Search results
Results from the WOW.Com Content Network
para-Bromomethamphetamine (PBMA; developmental code name V-111), also known as 4-bromomethamphetamine (4-BMA), is a monoaminergic drug of the amphetamine family ...
2 times a day bis die sumendum b.i.d., bid, BID twice a day / twice daily bis in die gtt., gtts drop(s) gutta(e) h., h hour: hora: qhs, h.s., hs at bedtime or half strength quaque hora somni ii two tablets duos doses iii three tablets trēs doses n.p.o., npo, NPO nothing by mouth / not by oral administration: nil per os o.d., od, OD right eye
para-Bromoamphetamine (PBA), also known as 4-bromoamphetamine (4-BA), is an amphetamine derivative which acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA) and produces stimulant effects. Another related compound is para-bromomethamphetamine (PBMA) known by the codename V-111. [1]
This is a list of abbreviations used in medical prescriptions, including hospital orders (the patient-directed part of which is referred to as sig codes).This list does not include abbreviations for pharmaceuticals or drug name suffixes such as CD, CR, ER, XT (See Time release technology § List of abbreviations for those).
[2] [3] It has since been used to treat a range of disorders from asthma to ADHD and illicitly for recreational purposes. Amphetamine-type stimulants contain chemical groups including unsubstituted phenyl ring , a methyl group at the alpha-position, and primary amino group, which accounts for its psychostimulant activities.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Studies in the 1970s found that a single dose of 10 mg/1 kg 4-CMA resulted in a decreased level of 5-hydroxytryptamine in the brain for several weeks. [ 12 ] 4-Chloromethamphetamine was identified outside of the laboratory for the first time at the Tomorrowland festival edition 2015, where a tablet was found in possession of a drug dealer (see ...
4-Bromofentanyl (para-bromofentanyl) is an opioid analgesic drug that is an analog of fentanyl and has been sold as a designer drug, [1] first identified in Pennsylvania in the US in March 2020. [ 2 ]